| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Avalo Therapeutics, Inc. (AVTX) has 9 insiders with recent SEC Form 4 filings, including 85 buys and 0 sells. AVTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 275.0K | $4.61M | - | |
| Other | 47.8K | $802.1K | -679 | |
| CFO | 19.1K | $320.8K | - | |
| Other | 3.6K | $61.0K | - | |
| Dir | 3.2K | $53.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2017 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 39,479 | $0.76 | $29,877.21 | - | |
| Aug 29, 2017 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 113,649 | $0.73 | $83,062.10 | - | |
| Aug 24, 2017 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 120,435 | $0.66 | $79,184.39 | - | |
| Aug 21, 2017 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 219,792 | $0.60 | $132,260.19 | +0.2% | |
| Aug 16, 2017 | Armistice Capital, LLC56 | 10% Owner | Buy | 954,228 | $0.61 | $585,091.92 | +0.7% | |
| Jun 9, 2017 | Hacksell Uli | Director | Buy | 20,000 | $0.75 | $14,900.00 | +200.0% | |
| May 19, 2017 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 72,672 | $0.63 | $45,783.36 | +0.7% | |
| May 11, 2017 | Armistice Capital, LLC56 | 10% Owner | Buy | 450,000 | $0.73 | $328,518.69 | +1.5% | |
| May 8, 2017 | Armistice Capital, LLC56 | 10% Owner | Buy | 2,592,858 | $0.49 | $1,277,942.22 | +4.2% | |
| Oct 20, 2015 | Marcus Ronald | Chief Medical Officer | Buy | 30,617 | $0.00 | - | +110.6% |